Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster
EloraTZP, which pairs tirzepatide with experimental drug eloralintide, outperformed tirzepatide alone in a 48-week Phase 2 trial in patients with obesity and type 2 diabetes
We haven't written up this one. Quartz has the full story — the link below goes straight to it.